Treatment continuity of MEK inhibitors and tumor trajectories after discontinuation in NF1 associated plexiform neurofibromas

Abstract Background: MEK inhibitors have improved the management of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs), but the relationship between treatment continuity and post-discontinuation tumor behavior in routine practice remains unclear. Methods: We retrospectively analyzed 40 patients with NF1-associated PNs treated with selumetinib or luvometinib at a tertiary referral center. Patients were classified as discontinuation or no discontinuation according to treatment continuity during follow-up. Outcomes were assessed using a harmonized T0/T1/T2 framework. Pain was evaluated using the Numeric Rating Scale (NRS), and longitudinal tumor change was measured in the same predefined target lesion. Results: Nineteen patients discontinued treatment and 21 remained on treatment. Compared with the no-discontinuation group, the discontinuation group showed less favorable tumor trajectories, with smaller tumor shrinkage at T1 (P = 0.0107), tumor regrowth at T2 relative to baseline (P < 0.0001), and greater tumor rebound (P < 0.0001). In paired analyses within the discontinuation group, median tumor volume changed from − 5.0% at T1 to 5.0% at T2 (P = 0.0003). Pain outcomes were more heterogeneous, with no significant between-group difference in pain rebound. Among patients who discontinued treatment, cost-related interruption was the most frequent documented reason (10/19, 52.6%). Conclusions: In this real-world NF1-PN cohort, treatment discontinuation was common and was associated with less favorable tumor trajectories over time. The clearest post-discontinuation signal was observed in tumor rebound, whereas symptom changes were more heterogeneous. Cost-related interruption was the most frequent documented reason for discontinuation, suggesting that financial burden may represent an important practical barrier to sustained MEK inhibitor therapy.

Authors

Institutions

Publication Details

Journal
Discover Oncology
Published
2026-11-14
DOI
https://doi.org/10.1007/s12672-026-06300-6
Primary Topic
Neurofibromatosis and Schwannoma Cases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Treatment continuity of MEK inhibitors and tumor trajectories after discontinuation in NF1 associated plexiform neurofibromas

Zhenlei Liu, Lei Zhang, Hao Wu
2 links
Discover Oncology
Neurofibromatosis and Schwannoma Cases
article

Treatment continuity of MEK inhibitors and tumor trajectories after discontinuation in NF1 associated plexiform neurofibromas

Zhenlei Liu, Lei Zhang, Hao Wu
article en

Abstract

Abstract Background: MEK inhibitors have improved the management of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs), but the relationship between treatment continuity and post-discontinuation tumor behavior in routine practice remains unclear. Methods: We retrospectively analyzed 40 patients with NF1-associated PNs treated with selumetinib or luvometinib at a tertiary referral center. Patients were classified as discontinuation or no discontinuation according to treatment continuity during follow-up. Outcomes were assessed using a harmonized T0/T1/T2 framework. Pain was evaluated using the Numeric Rating Scale (NRS), and longitudinal tumor change was measured in the same predefined target lesion. Results: Nineteen patients discontinued treatment and 21 remained on treatment. Compared with the no-discontinuation group, the discontinuation group showed less favorable tumor trajectories, with smaller tumor shrinkage at T1 (P = 0.0107), tumor regrowth at T2 relative to baseline (P < 0.0001), and greater tumor rebound (P < 0.0001). In paired analyses within the discontinuation group, median tumor volume changed from − 5.0% at T1 to 5.0% at T2 (P = 0.0003). Pain outcomes were more heterogeneous, with no significant between-group difference in pain rebound. Among patients who discontinued treatment, cost-related interruption was the most frequent documented reason (10/19, 52.6%). Conclusions: In this real-world NF1-PN cohort, treatment discontinuation was common and was associated with less favorable tumor trajectories over time. The clearest post-discontinuation signal was observed in tumor rebound, whereas symptom changes were more heterogeneous. Cost-related interruption was the most frequent documented reason for discontinuation, suggesting that financial burden may represent an important practical barrier to sustained MEK inhibitor therapy.

Discover Oncology
Capital Medical University (CN), Xuan Wu Hospital of the Capital Medical University (CN)
Good health and well-being
Neurofibromatosis and Schwannoma Cases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon